INTRODUCTION
============

The Night Eating Syndrome (NES) is an emerging disease of feeding behavior, considered a eating disorders not otherwise as classified in the DSM IV TR, which combines eating disorders, sleep, mood and stress. Basically the NES is characterized by a reduced feeding during the day, evening hyperphagia accompanied by difficulty falling asleep (initial insomnia) and maintaining sleep with nocturnal awakenings associated with aware episodes of compulsive ingestion of food, due to a sudden craving that goes beyond a real feeling of hunger and a subsequent recovery sleep impossible without having taken food. In recent years, the NES is gaining more and more interest in close association with obesity \[[@R1]-[@R4]\]

Allison *et al*. \[[@R5]\] proposed new criteria for diagnosis of the NES. This research has established two core criteria: (1) the consumption of at least 25% of daily caloric intake after the evening meal and/or (2) evening awakenings with ingestions at least twice per week. Five descriptors have been added to the core criteria, three of which are required for the diagnosis of NES. Additionally, persons must be aware of their nocturnal ingestions, they must experience distress or impairment in functioning, and they must have experienced the signs and symptoms for the past 3 months \[[@R5]\]. These criteria help standardize the definition of NES. Additional aspects of the nosology of NES yet to be fully elaborated include its relationship to other eating and sleep disorders. Assessment and analytic tools are needed to assess these new criteria more accurately \[[@R5]\].

In this way the NES can be clearly distinguished from other related diseases such as binge eating disorder or sleep-related eating disorder. The authors conclude that a clearer connotation nosographic allow a better definition for the prevalence, its association with obesity, the assessment of the frequent comorbidity and a more effective determination of the underlying biological implications \[[@R5]\].

Therefore, NES appears to be a combination of an eating disorder, a sleeping disorder and a mood disorder \[[@R4]-[@R6],[@R31]\].

Altering the timing of food intake, typical of NES, is related to abnormal neuroendocrine patterns. The blood levels of cortisol, albeit measured on a limited number of studies are on average higher and lower circadian fluctuations, and appears to increase the production of TSH \[[@R7],[@R8]\], similar to stress-related disorders \[[@R9]\].

Several studies also show that people with the NES have lowered levels of melatonin which is the naturally occurring hormone that regulates the body's circadian rhythms that control the biochemical, the physiological and the behavioral 24-hour cycles such as sleep and many others \[[@R7]\]. Therefore, it is believed that the decreased melatonin is a big contributor to disturbances of sleep and the onset of the night eating syndrome. Additional factors that contribute to the NES and its night binging are leptin \[[@R7]-[@R9]\] (the hormone that is believed to suppress appetite and speed up metabolism), certain medications and highly restrictive and prolonged dieting among obese individuals. Even the regulation of ghrelin \[[@R9]\], an endogenous ligand receptor growth hormone (GH), which affects not only food but also control induction of sleep is altered in the NES \[[@R9]\].

Emotional factors such as [depression]{.ul}, anxiety, stress, boredom, low self esteem and skewed body image play a significant role in the NES and they are the catalysts that lead to night binging on comfort foods that have high caloric values from their carbohydrates and fat contents \[[@R10]\]. Often in patients with NES are found, and in patients with other eating disorders, significant comorbid psychopathology such as depression and anxiety \[[@R15]\]. Patients with NES often have higher scores on Beck Depression Inventory Scale and the Zung Depression Scale compared with controls \[[@R10]\] with a chance of lifetime incidence of major depression of 55% DM \[[@R11]\]. But often in patients with NES is the decline in mood in the evening and at night, in the opposite way to experience clinical depression typical \[[@R12]\]. There are also frequent, although symptoms related to a condition of anxiety and worthlessness \[[@R13],[@R14]\].

The NES is treatable but it is not easy, since, in most instances, the patients are unaware of their conditions and are, therefore, resistant treatment.

In this respect, treatment for NES, because of the complexity of diagnosis, has to be done on an individual basis, combining mental health therapy, education on diet and nutrition, possibly medication to reduce stress, time spent in a sleep lab for observation and a great deal of support. This particular disorder is showing signs of responding favorably to the antidepressants such as SSRIs (Selective Serotonin Re-uptake Inhibitors). These have been found useful due to their effect on the serotonin levels in the brain. Serotonin promotes calm and helps counteract cravings and is involved in the production of melatonin which aids sleep. And this ties in with a theory that by binge eating mainly on high carbohydrate foods, the NES sufferer is (subconsciously) self-medicating themselves, as when carbohydrates are eaten, they allow an amino acid called tryptophan to cross the blood / brain barrier to be used in the production of serotonin.

However, currently trials on pharmacological treatments of NES are still at a preliminary stage. Some literature data suggest that two types of drugs seem likely to be effective in reducing episodes of NES:

1\. anticonvulsants such as topiramate \[[@R16]\].

2\. selective serotonin reuptake inhibitors (SSRIs) \[[@R17]-[@R19]\].

Given the strong relationship between NES, cycles sleep and food alteration, as well as the frequent presence of depressed mood, associated with lower circulating levels of melatonin in the evening and at night, the treatment of NES with agomelatine, a melatonin agonist, may be considered.

Agomelatine is a potent agonist of MT1 and MT2 receptors, they are present in various areas of the brain especially at the level of the suprachiasmatic nucleus, hippocampus, hypothalamus and cerebellum and it is also an antagonist of serotonergic 5-HT2c receptors, while the affinity for other receptors is negligible \[[@R20],[@R21]\]. The affinity for the MT1 and MT2 receptors *in vivo* is 5 times higher than that for serotoninergic and being agomelatine a highly lipophilic substance able to cross the blood-brain barrier and reaches micromolar concentrations sufficient to exert its action on both types of receptors. Furthermore, despite the agomelatine is not a monoamine reuptake inhibitor, has been shown a dose-dependent increase of extracellular concentrations of dopamine and norepinephrine selectively at the level of the frontal cortex \[[@R20]-[@R22]\]. Recent evidence has shown that agomelatine increases the expression of the \"brain-derived neurotrophic factor\" (BDNF), a trophic factor and a marker of neuroplasticity, which is believed to have an important role in mood disorders, in the prefrontal cortex and hippocampus. In addition, it also increases the expression of \'\"activity-regulated cytoskeleton-associated protein\" (ARC), which is involved in the sleep / wake cycle at the level of the prefrontal cortex \[[@R23]-[@R26]\]. Therefore chronic therapy with agomelatine has been shown to increase neurogenesis in hippocampal level, to lengthen the survival of neuronal cells and to attenuate the release of glutamate induced by stress at the cortical level \[[@R27]\]. These results indicate that agomelatine acts through a synergistic action on receptors and MT1/MT2 5HT2c, leading to a re-synchronization of circadian rhythms through an effect on the \"clock genes\", the release of glutamate, the expression of BDNF, ARC and on neurogenesis \[[@R28]\] (Fig. **[1](#F1){ref-type="fig"}** and **[2](#F1){ref-type="fig"}**).

Participant and Procedures
==========================

At the Mental Health Division of the District 24 ASL Napoli 1 Centre, we have followed five patients affected by the NES according to the criteria of the First International Symposium Night Eating Diagnostic Criteria and depressed mood, according to the criteria of the DSM-IV-TR, in comorbidity. All patients, 3 females and 2 males, aged between 32 and 45 years, were treated with agomelatine 25 mg / day for the first two weeks and 50 mg / day for the next 10 weeks. Before the observation period, all patients studied showed a number of anthropometric measurements such as height, weight and BMI, HAM-D (Hamilton Rating Scale for Depression) and NEQ (Night Eating Questionnaire), dose glucose, insulin, total cholesterol and HDL, triglycerides and liver transaminases (ALT and AST) in the fasted state. They also performed a polysomnography which measured the number of nocturnal awakenings, minutes of snoring and movement per night. At the end of the observation period of three months all these measurements were repeated. Every two weeks the patients were followed for a controlled outpatient clinical evaluation and to verify the possible occurrence of adverse events related to treatment.

ASSESSMENT MEASURES
===================

The study involved the administration of two scales, before and after observation: The Night Eating Questionnaire (NEQ) \[[@R29]\] and Hamilton Depression Rating Scale - HDRS or HAM-D \[[@R30]\]. Both measures are self-administered and takes about an hour to administer both. The NEQ consists of 15 items and participants who reported on the NEQ consuming ≥25% of their caloric intake after their evening meal or the presence of nocturnal ingestions (waking after sleep onset to eat) were asked follow-up questions to confirm the extent of evening hyperphagia, frequency of nocturnal ingestions, and the context of their night eating behavior. The NES interview included an outline of the general pattern of food intake for a typical 24-hour period and a specific recall of all food consumed after the evening meal 2 nights before the interview, provided it was representative of a typical evening\'s food intake.

Hamilton Depression Rating Scale (HDRS) or abbreviated to HAM-D, is a multiple choice questionnaire that clinicians may use to rate the severity of a patient\'s major depression. The scale examines several different areas that are critical to the evaluation of the depressive state of the subject. The areas are: depressed mood, guilt, suicidal ideation, initial insomnia, middle insomnia, insomnia, prolonged work and interests, slowing of thought and words , agitation, anxiety, psychic source, somatic anxiety, gastrointestinal somatic symptoms, general somatic symptoms, genital symptoms, hypochondriasis, introspection, weight loss, diurnal variation of symptoms, depersonalization, paranoid symptoms, obsessive symptoms.

Polysomnographic Recordings
===========================

It is a instrumental test that records, during sleep the presence of snoring, heart rate and electrocardiogram, body position of the subject, the saturation of blood, the respiratory movement and airflow. It is a test that is performed at the patient\'s home. The execution of polysomnography involves applying three electrodes to the chest, a finger pulse oximeter and a breath meter outside the nose during sleep, a small computer (Embletta Somnografica) to which all sensors are connected with the main parameters respiration and heart activity.

RESULTS
=======

At the end of the 12 weeks of observation period, all patients treated with agomelatine showed an improvement in symptoms of NES characterized by lower scores on the HAM-D passing from the mean value of 23.2 to 14.2 (reduction of 65.5 %), the NEQ values ​​passing from the mean value of 31 to 22.8 (73.5% reduction), the weekly average number of awakenings was reduced from 12 to 6.4 and the average weight passing from 81, 6 to 78 kg with an average reduction of 3.6 kg with a mean BMI from 29.5 to 28.7 as assessed by polysomnography and the average snoring in percentage was reduced from 7.7% to 6.2% while the average movement in share has increased from 6.5% to 5.1%.

Hematochemical indices assessed before and after treatment, remained stable with a small reduction in blood glucose, total cholesterol and triglycerides while ALT and AST showed a slight increase. (Table **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**). None of the patients studied, showed significant adverse events related to treatment with agomelatine.

CONCLUSIONS
===========

The data reported in this observational study demonstrated the agomelatine efficacy in the treatment of NES. All the symptomatology characteristic of this food pathology are improved during the observation period.

NES is often accompanied by changes not only of the circadian rhythms of sleep and food, with frequent awakenings associated with compulsive ingestion of food in non-REM stages of sleep \[[@R2]\] but also to alterations of cortisol secretion and other hormones \[[@R2]\]. Agomelatine is able to regulate the stressor-induced overactivity of the pituitary-adrenal axis (HPA), by improving the sleep slow wave (SW), without reducing REM sleep and by helping the synchronization of circadian rhythms \[[@R20],[@R21]\].

Decreasing values ​​of the NEQ 73.5% (mean values from 31 to 22.8) show an improvement of the NES core symptoms, with better sleep quality, reduction of dayligh ipofagia, reducing need to eat in the evening and night. Even nocturnal awakenings were reduced from a week average of 12 to 6.4, with a reduction of 53.3%. Polysomnographic recordings also showed an improvement in the sleep quality with a significative reduction of snoring (in minutes from 7.7 to 6.2%) as well as a significative reduction of night time movements (from 6.5 to 5.1%).

An improvement, albeit of partial entities, there was also on the weight, going from an BMI average of 29.5 to 28.7, with an average reduction of 3.6 kg during the three months of treatment, probably due to a reduction of evening and night food-intake with a better balance energy intake throughout the day.

Also, thanks to the synergic action on receptors MT1 and MT2 agonist and 5-HT2C antagonistic properties (Fig. **[1](#F1){ref-type="fig"}**), agomelatine is able to significantly improve mood and to reduce anxiety component, both frequently present in the NES comorbidities.

The depressive component, present in comorbidity in all five of our patients, is improved significantly, as indeed was to be expected with the use of agomelatine, as evidenced by the reduction of 65.5% of the HAM --D values (going from average values ​​of 23.2 to 15.2).

During the entire period of treatment, we did not detected adverse events related to drug, but only a mild increased of trasaminasi. However, even with all the limitations related to an observational study because of limited number of clinical cases without an adequate placebo control, agomelatine may be considered very useful in the treatment of NES. Of course these preliminary data will be confirmed by controlled trials on a sample numerical wider and for a period of time more extended.
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Therefore, in the present paper we report the effect of agomelatine in five NES patient.](TONEUJ-7-32_F1){#F1}

###### 

Evaluation Parameters of the Five NES Patients Studied

  Patients                                                                    
  --------------------------------------- ------- ------ ------ ------ ------ -----
  Weight Kg                               97      90     65     76     80     
  BMI                                     31,5    31     27,5   29     30     
  HAM-D 17                                27      22     24     19     24     
  NEQ                                     34      31     28     30     32     
  Number of awakenings average per week   16      14     8      11     12     
  Snoring in minutes (%)                  9,38    6,36   6,1    4,6    12,4   
  Movements in minutes (%)                5,3     5,7    3,5    7,8    10     
  Glycemia                                mg/dl   122    112    89     96     110
  Insulinemia mU/ml                       26      11     8      14     22     
  Cholesterol tot. mg/dl                  288     226    195    210    238    
  Cholesterol HDL mg/dl                   40      45     50     48     40     
  Tryglicerides mg/dl                     270     178    165    145    230    
  AST                                     U/l     29     22     12     19     24
  ALT                                     U/l     32     28     19     34     22
  After 12 weeks agomelatine treatment                                        
  Weight Kg                               92      88     64     73     73     
  BMI                                     30      30,5   27     28,5   27,5   
  HAM-D 17                                18      12     14     16     16     
  NEQ                                     24      22     18     24     26     
  Number of awakenings average per week   9       8      3      5      7      
  Snoring in minutes (%)                  6,8     5,5    5,9    4,2    8,6    
  Movements in minutes (%)                4,8     4,2    4,2    5,7    6,9    
  Glycemia                                mg/dl   98     105    92     92     84
  Insulinemia mU/ml                       24      14     7      15     18     
  Cholesterol tot. mg/dl                  262     208    192    176    222    
  Cholesterol HDL mg/dl                   45      46     52     46     42     
  Tryglicerides mg/dl                     212     166    158    152    196    
  AST                                     U/l     32     26     16     28     28
  ALT                                     U/l     36     26     26     38     24

###### 

Total Outcome for the Five Patients Before and After Treatment

                                          Before   After                        
  --------------------------------------- -------- ------- ----------------- -- --
  Weight Kg                               81,6     78      -3,6                 
  BMI                                     29,5     28,7    -0,8                 
  HAM-D 17                                23,2     15,2    65,5% reduction      
  NEQ                                     31       22,8    73,5% reduction      
  Number of awakenings average per week   12       6,4     53,3% reduction      
  Snoring in minutes (%)                  7,7      6,2                          
  Movements in minutes (%)                6,5      5,1                          
  glycemia                                mg/dl    105     94                   
  Insulinemia mU/ml                       16       15,6                         
  Cholesterol tot. mg/dl                  231      212                          
  Cholesterolo HDL mg/dl                  46       44                           
  Tryglicerides mg/dl                     197      176                          
  AST                                     U/l      21      26                   
  ALT                                     U/l      27      30                   
